SCHEMBL30765617

SCHEMBL30765617

CC(C)(Nc1cnc(-c2ccccc2F)n(CC(=O)NCc2cc3cnccc3[nH]2)c1=O)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
F3 P13726 4/20 0.34
F2 P00734 4/20 0.34
HDAC6 Q9UBN7 2/20 0.33
PRSS1 P07477 1/20 0.33
PRSS2 P07478 1/20 0.33
PRSS3 P35030 1/20 0.33
ALDH1A1 P00352 2/20 0.32
HPGD P15428 1/20 0.32
HDAC1 Q13547 1/20 0.32
NAMPT P43490 2/20 0.32
LMNA P02545 1/20 0.32
CMA1 P23946 2/20 0.32
CTRC Q99895 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765829 0.85 F3 (0.34) F3F2PRSS1PRSS2PRSS3
SCHEMBL31558576 0.85 F3 (0.35) F3F2HDAC6PRSS1PRSS2
SCHEMBL30765439 0.85 F3 (0.35) F3F2HDAC6PRSS1PRSS2
SCHEMBL30765945 0.85 F3 (0.34) F3F2PRSS1PRSS2PRSS3
SCHEMBL30765861 0.84 F3 (0.36) F3F2ALDH1A1HPGDLMNA
SCHEMBL30765595 0.84 F3 (0.35) F3F2PRSS1PRSS2PRSS3
SCHEMBL30765964 0.82 GABRP (0.38) HDAC6ALDH1A1HPGDLMNA
SCHEMBL30765565 0.81 F3 (0.36) F3F2PRSS1PRSS2PRSS3
SCHEMBL30765885 0.80 MAPK1 (0.34) F3F2HDAC6PRSS1PRSS2
SCHEMBL30765751 0.80 F3 (0.34) F3F2PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed